NCT04760652View on ClinicalTrials.gov

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention

NACompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Depression and Suicide
Interventions
BEHAVIORAL

Cognitive Behavioral Therapy CBT

CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT

Trial Locations (3)

30329

Emory University, Atlanta

Alabama

"UAB Medicine , Heersink School of Medicine"

06511

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Yale University

OTHER

NCT04760652 - Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention | Biotech Hunter | Biotech Hunter